Lumata Health Elevates Its Mission with New Clinical Advisory Board
Lumata Health Elevates Its Mission with New Clinical Advisory Board
In a significant move for the future of eye care, Lumata Health has announced the formation of a new Clinical Advisory Board (CAB). This initiative aims to strengthen their platform dedicated to preventing blindness among individuals at risk from chronic eye diseases.
Expert Guidance and Vision
The Clinical Advisory Board consists of five accomplished ophthalmologists, each with a wealth of knowledge and experience in tackling the leading causes of vision loss. This board will play an indispensable role in guiding Lumata's strategies and ensuring the company stays at the forefront of eye care advancements.
Insights from Leadership
"Our Clinical Advisory Board is made up of some of the brightest minds in ophthalmology," stated Landon Grace, CEO and co-founder of Lumata Health. "Their insights will help us enhance our patient support initiatives which complement the clinical care provided by physicians. We are committed to growing the number of patients we serve by over 200% annually." This dedication exemplifies Lumata’s commitment to improving patient outcomes dramatically.
Data-Driven Continuous Care
A crucial focus for the CAB will be the enhancement of Lumata's data-driven continuous care model. By leveraging the latest behavioral insights and clinical data, they aim to offer personalized care solutions that significantly improve patient adherence. For instance, a study showed that a group of 100 patients in Lumata's program attended 72 more office visits in a year than matched controls, highlighting the effectiveness of their approach.
The Role of Care Coaches
"Lumata Health serves as a vital link in addressing care adherence for millions at risk of blindness. We act as Care Coaches, navigating patients through appointments, medications, and supporting their health journeys, all backed by the latest technology and delivered with a human touch," remarked Dr. Benjamin Kunz, Chair of the Clinical Advisory Board. This human-centric approach is integral to enhancing patient experiences and outcomes.
Expanding the Reach of Care
Joining the CAB are distinguished doctors including Andrew McClellan, MD; Sumit P. Shah, MD, FACS, FASRS; Murtaza Adam, MD; and Swarup Swaminathan, MD. Their collective efforts will not only focus on clinical excellence but also on expanding Lumata's reach within communities at risk.
Importantly, Lumata Health’s continuous care services fall within Medicare’s Chronic Care Management billing codes, often at no extra cost to the patient. This program aids in lowering the expenses related to prescriptions and removes barriers to care access, ensuring that patients receive the necessary support they deserve.
Respected in the Eye Care Community
More than 1,400 ophthalmologists now trust Lumata Health’s platform, which plays a vital role in managing care for over 25,000 patients suffering from chronic eye diseases such as glaucoma, diabetic retinopathy, and macular degeneration. This growing network underscores the efficacy and reliability of Lumata's services in the healthcare sector.
To date, Lumata Health boasts over $14.8 million in funding, reflecting significant investor confidence in their innovative approach to eye care management.
About Lumata Health
Founded in 2017 by Dr. Stephen R. Fransen, an ophthalmologist with over 30 years of experience, Lumata Health is driven by a mission to eliminate preventable blindness through a human-led, technology-focused care management strategy. The organization collaborates with healthcare partners to offer tailored management services aimed at enhancing clinical outcomes while relieving burdens on clinics.
For further information about Lumata Health, please visit lumatahealth.com.
Frequently Asked Questions
What is the purpose of Lumata Health's new Clinical Advisory Board?
The CAB aims to provide strategic guidance to Lumata Health in reducing preventable blindness and enhancing continuous patient care through innovative technology.
Who are the members of the Clinical Advisory Board?
The CAB includes renowned ophthalmologists like Andrew McClellan, MD; Sumit P. Shah, MD; Murtaza Adam, MD; and Swarup Swaminathan, MD.
How does Lumata Health support patient adherence?
By implementing a data-driven continuous care model that connects patients with Care Coaches, Lumata Health enhances patient adherence to treatment plans and appointments.
What types of eye diseases does Lumata Health address?
Lumata Health focuses on chronic eye diseases such as glaucoma, diabetic retinopathy, and macular degeneration.
How is Lumata Health funded?
The organization has raised over $14.8 million in funding, showcasing strong backing from investors confident in its mission and technology.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.